DAX ®13.198,37-0,23%TecDAX ®2.928,35+0,24%Dow Jones27.691,49+0,04%NASDAQ 1008.241,91-0,17%

EQS-News: Polyphor to present at the H.C. Wainwright Global Investment Conference

| Quelle: Dow Jones Newsw... | Lesedauer etwa 3 min. | Text vorlesen Stop Pause Fortsetzen

EQS Group-News: Polyphor AG / Key word(s): Conference
Polyphor to present at the H.C. Wainwright Global Investment Conference

2019-09-04 / 17:38

_Allschwil, Switzerland, September 4, 2019_

*Polyphor to present at the H.C. Wainwright Global Investment Conference*

Polyphor AG (SIX: POLN) today announced that the company will present at the
21st Annual H.C. Wainwright Global Investment Conference, taking place
September 8-10, 2019 in New York City. Giacomo Di Nepi, CEO of Polyphor,
will provide an overview of the company and its pipeline and will be
available to participate in one-on-one meetings with investors who are
registered to attend the conference. A live webcast of the presentation will
be accessible on Polyphor's website on the Investor Relations page on the
Calendar tab or under the following link: Polyphor Webcast [1]. A replay of
the webcast will be available for 90 days following the conclusion of the

*Presentation details:*
Date: September 9, 2019
Time: 03:25 - 03:50 pm EDT
Location: The Lotte Palace Hotel, New York
Webcast: Polyphor Webcast [1]

*For further information please contact:*

*For Investors:*
Kalina Scott
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 67
Email: IR@polyphor.com

*For Media:*
Alexandre Müller
Dynamics Group AG
Tel: +41 43 268 32 31
Email: amu@dynamicsgroup.ch

*About Polyphor*
Polyphor is a clinical stage, Swiss biopharmaceutical company focused on the
discovery and development of immuno-oncology compounds and a new class of
antibiotics. Polyphor is advancing balixafortide (POL6326) in a Phase III
trial in combination with eribulin in patients with advanced breast cancer,
and exploring its potential in other cancer indications. In addition, it has
discovered and is developing the Outer Membrane Protein Targeting
Antibiotics (OMPTA). OMPTA are potentially the first new class of
antibiotics in clinical development in the last 50 years against
Gram-negative bacteria. The company's lead OMPTA program is an inhaled
formulation of murepavadin for the treatment of Pseudomonas aeruginosa
infections in patients with cystic fibrosis. Polyphor is based in Allschwil
near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more
information, please visit www.polyphor.com [2].

Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=SOIKULNSGV [3]
Document title: Polyphor_Wainwright_4.9.2019

End of Corporate News
Language: English
Company: Polyphor AG
Hegenheimermattweg 125
4123 Allschwil
Phone: +41 61 567 1600
Fax: +41 61 567 1601
E-mail: info@polyphor.com
Internet: www.polyphor.com
ISIN: CH0106213793
Listed: SIX Swiss Exchange
EQS News ID: 868721

End of News EQS Group News Service

868721 2019-09-04

1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=4624b81c5bbd30e576c8c9b4bfc30efd&application_id=868721&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=ee6c0538a597dfcdf52d3305a6c85670&application_id=868721&site_id=vwd&application_name=news
3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=31be20f67fa05f3a33840bf0c0add067&application_id=868721&site_id=vwd&application_name=news

(END) Dow Jones Newswires

September 04, 2019 11:39 ET ( 15:39 GMT)

Das könnte Sie auch interessieren



Aktuelle Videos

zur Mediathek

Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.